Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Grifols Shared Services North America Inc. maintains a presence in the Biotechnology & Pharmaceuticals technology area with 1 pending office action currently on the docket. This 1 pending office action represents the state of the company's active patent negotiations. The number of actions reflects a selective prosecution strategy within the pharmaceutical space.
The portfolio's review process is centralized, involving 1 distinct examiner and 1 distinct art unit. Having 1 distinct art unit involved means the company's current technical disclosures are being evaluated against a specific set of internal guidelines. This concentration allows for a specific dialogue between the applicant and the 1 distinct art unit at the patent office, potentially leading to more predictable outcomes.
The busiest examiner for this portfolio is BEANE, RANDALL L, who is currently responsible for 1 busiest examiner pending office action. Because the total number of actions is 1, this examiner handles the active matters for the company. The 1 busiest examiner pending office action indicates that the outcome of the current prosecution efforts rests with this examiner's determination, highlighting the importance of the 1 distinct examiner in the current strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BEANE, RANDALL L | 1 | 32.8% | +36.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17146912 | METHOD FOR REDUCING THE OCCURRENCE OF THROMBOSIS OR THROMBOEMBOLISM | BEANE, RANDALL L | 28d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17146912 | METHOD FOR REDUCING THE OCCURRENCE OF THROMBOSIS OR THROMBOEMBOLISM | BEANE, RANDALL L | 28d |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17146912 | METHOD FOR REDUCING THE OCCURRENCE OF THROMBOSIS OR THROMBOEMBOLISM | BEANE, RANDALL L | 1654 | §102§103§112 | Final Rejection | 28d | Pending | Jan 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial